Stay updated on ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page’s displayed software/version label has been updated from **Revision v3.5.2** to **Revision v3.5.3**, indicating an interface or site release update without affecting the underlying study record content.SummaryDifference0.0%

- Check16 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check24 days agoChange DetectedAdded the new study title A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer (MUIR) and expanded the description of the Phase 1b study design, including Part 1 and Part 2, dose escalation and expansion with bevacizumab. Updated the page to Completed status with an enrollment target of 172 and a primary completion date of 2028-06-30, replacing the previous version.SummaryDifference3%

- Check45 days agoChange DetectedRevision v3.5.0 was added and v3.4.3 was removed.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing the previous v3.4.2.SummaryDifference0.0%

- Check81 days agoChange DetectedFallopian tube cancer was added to the study's conditions, and the page revision was updated to v3.4.2 (v3.4.1 was removed).SummaryDifference0.1%

Stay in the know with updates to ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial page.